Articles by Peter Kissinger

It takes real strength of character to accept the high risk in pharma and biotech and not be psychologically crippled by it

Many don’t realize how little “settled science” we’ve got, and the last nine months have brought science out front on a new scale

More meetings are going virtual, and that may very well be a good thing even after COVID is no longer a pandemic

Diagnostic testing is hotter news right now with COVID than perhaps ever before, but what does it all mean?

Counting publications is appealing in its simplicity and we all do that. The capacity for words and numbers no longer depends on paper and ink; a consequence of this system (for biomarkers and other research) may well relate to irreproducible scientific papers going viral, often from the most prestigious journals

Peter Kissinger follows up his December column with a "part 2" talking about the cost-benefit ratio in the life sciences

Drug prices may be too expensive, but some of the answers being touted might not be the best ones, says DDNews columnist Peter Kissinger, who shares some of his thoughts of the pros and cons of various notions

While we are increasingly able to make better drug choices for subpopulations thanks to companion diagnostics and more, actually optimizing dosing for an individual is an aspirational goal right now

As he retires from teaching at the university level (though he's not yet from retired from life sciences), columnist Peter Kissinger reflects on the past five decades of experiences and his observations of our industry

There is a balance that is necessary in research and development, so let's not lose sight of keeping it overall, even if many individual people (and companies and institutions) often trend more one direction or the other

There are plenty of new areas to explore in therapeutic options for all diseases and conditions that vex us, but are we straying too far from reliable ground and ignoring good options in the process?

We have seen information technology anxiety run rampant in the past (with Y2K); today's worries about cyber security, fake news, autonomous robotics and artificial intelligence are nothing new...but they are worth noting nonetheless

The will to understand vs. the will to obscure is not a new theme, but when blended with electronic communications it is given new intensity

Opportunities for Ph.D. students entering the workforce go beyond just academia

Medicine is moving decade by decade to be more information-rich and constrained by the resulting increases in cost from advances in both the physics and the chemistry; the tools in the black bag of 1960 are not enough for today’s best result